"We are delighted that we have achieved this key milestone in
our AML program," said Dr. Wayne Danter, CEO. "The successful
synthesis and initiation of the preclinical evaluation of the
first candidates from our third major drug discovery program
provides further validation of CHEMSAS® as a powerful
artificial intelligence drug discovery engine. Successful
candidates from this program will provide additional valuable
commercial assets that can be licensed to partners for
further development."
Like many other cancers, AML is the result of multiple gene
mutations that affect multiple cell signaling kinase
pathways. With few exceptions, traditional therapies that
target a single abnormal kinase have produced disappointing
long
Critical Outcome Technologies Inc. Other OTC
Equities
CA22675B1031
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+20.63% | 13TCr | |
+24.89% | 2.77TCr | |
-20.17% | 2.03TCr | |
-16.71% | 1.68TCr | |
-18.07% | 1.56TCr | |
-47.70% | 1.46TCr | |
+11.92% | 1.48TCr | |
+58.32% | 1.44TCr | |
+149.98% | 1.25TCr |